Development of Acquired Resistance in Alpelisib-treated Gastric Cancer Cells With<i>PIK3CA</i>Mutations and Overcoming Strategies
Mingu Kang(Seoul National University), Keun‐Wook Lee(Seoul National University Bundang Hospital)
Cited by 1
Related Papers
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|291
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
|Journal of Clinical Oncology|2023|100
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study
|Seoul National University Open Repository (Seoul National University)|2021|95